NeoGenomics (NEO) investor relations material

Executive summary

• Q3 revenue was $209.254M, up 11.4% YoY; clinical revenue grew 13%, including 29% NGS growth, while adjusted EBITDA rose 53% to $18.669M.

• FY 2026 revenue and adjusted EBITDA guidance increased; strategic priorities include NGS growth, MRD adoption and disciplined margin expansion.

Financial highlights

• Q3 gross profit was $96.588M, up 20.1% YoY; operating loss improved to $7.941M from $27.014M, and net loss narrowed to $7.546M from $27.1M.

• Adjusted gross margin was 48.6%, up 310 bps YoY; adjusted EBITDA margin was 8.9%, up 240 bps.

• Adjusted net income was $10.5M versus $3.6M; adjusted diluted EPS was $0.07 versus $0.03.

• Operating expenses were $104.5M; adjusted YoY comparison was up 4% excluding $7.1M of Q3 2025 impairment charges.

• Nine-month revenue rose 11.2% to $597.582M; net loss narrowed to $22.414M from $98.144M, and adjusted EBITDA reached $42.140M.

Outlook and guidance

• FY 2026 revenue guidance rose to $807M–$809M, implying ~11% growth at the midpoint; adjusted EBITDA guidance increased to ~$60M.

• Guidance assumes low-teens clinical revenue growth, NGS growth above 25%, non-clinical revenue down low double digits, and adjusted gross margin expansion exceeding 150 bps.

• FY 2026 GAAP net loss guidance improved to $30M–$32M; adjusted net income guidance is $27M–$28M and adjusted diluted EPS $0.21–$0.22.

• FY 2026 capex was forecast at $35M, with $25M spent in the first nine months; R&D spending and sales commissions are expected to rise.